Research programme: T-cell therapies- Triumvira

Drug Profile

Research programme: T-cell therapies- Triumvira

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator Triumvira
  • Class Cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; CD19 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical B cell lymphoma; Leukaemia; Multiple myeloma; Ovarian cancer
  • Research Solid tumours

Most Recent Events

  • 28 Jun 2016 Preclinical trials in Ovarian cancer in Canada (unspecified route)
  • 28 Jun 2016 Triumvira Immunologics plans a clinical trial before June 2016
  • 25 Apr 2016 Early research in Solid tumours in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top